A Phase 1a/1b Study of SBP-101 in Previously Treated Subjects with Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

Trial Profile

A Phase 1a/1b Study of SBP-101 in Previously Treated Subjects with Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs SBP 101 (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions; First in man
  • Sponsors Sun BioPharma
  • Most Recent Events

    • 04 Oct 2017 According to a Sun BioPharma media release, the Data Safety Monitoring Board (DSMB) has reviewed data from the sixth and final cohort of patients, as well as data from all 29 patients enrolled in the study.
    • 04 Oct 2017 Results (n=29) published in the Sun BioPharma Media Release
    • 05 Sep 2017 Planned End Date changed from 1 Dec 2017 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top